Kannalife Spokesman Nick Lowery Wins 2018 CNBC Stock Draft
February 05 2019 - 9:00AM
Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and
phyto-medical company, is pleased to announce and congratulate the
Company’s spokesperson – former NFL and Kansas City Chiefs Hall of
Famer – Nick Lowery for winning the 2018 CNBC Stock Draft with his
picks of Amazon (Nasdaq:AMZN), Goldman Sachs (NYSE:GS) and AMD
(Nasdaq:AMD).
Nick’s incredible acumen for business played
itself out in 2018 as he was awarded top honors in the annual CNBC
Stock Draft. We also extend our appreciation and recognition for
his accomplishments and humanitarian efforts. Nick was just honored
with the 2019 Steinberg DeNicola Humanitarian Award during
Superbowl LIII week in Atlanta, and will be the honoree at the
American Cancer Society’s 58th Annual Evening of Hope on February
16th, 2019 in Phoenix, Arizona.
Dean Petkanas, CEO of Kannalife, stated, “It is
an honor and a privilege to have Nick Lowery as a part of our team
at Kannalife in support of our efforts to combat neurodegenerative
and oxidative stress related diseases in the emerging field of
cannabinoid therapeutics.”
About Kannalife, Inc. – A Phyto-Medical
Company™ Kannalife, Inc. is a phyto-medical company
involved in the research and development of novel therapeutic
agents designed to be neuroprotectants and immuno-modulators.
Kannalife is currently conducting research and development at the
Pennsylvania Biotechnology Center in Doylestown, PA, for target
drug candidates to treat hepatic encephalopathy (“HE”), chronic
traumatic encephalopathy (“CTE”) and Chemotherapy Induced
Peripheral Neuropathy (“CIPN”). HE and CTE are oxidative
stress-related diseases that affect cognitive and behavioral
functions. CIPN is a neurodegenerative condition that afflicts
patients undergoing chemotherapy with symptoms that include
numbness, tingling, and pain.
For more information, visit
www.kannalife.com.
FORWARD-LOOKING DISCLAIMER AND
DISCLOSURESThis press release may contain certain
forward-looking statements and information, as defined within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and is subject to the
Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results
that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements by definition
involve risks and uncertainties. The statements in this press
release have not been evaluated by the FDA and are not intended to
diagnose, treat or cure any disease. The Company does not sell or
distribute any products that are in violation of the United States
Controlled Substances Act.
CONTACT:
Public Relations Contact:Andrew HardChief
Executive OfficerCMW MediaP: 888-829-0070andrew.hard@cmwmedia.com
www.cmwmedia.com
Goldman Sachs (NYSE:GS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Goldman Sachs (NYSE:GS)
Historical Stock Chart
From Apr 2023 to Apr 2024